Description     Claims     Drawing  

US61861989   [0001] 
WO2013079473A   [0005] 
US6465425B   [0106] 
US7037894B   [0117]  [0118]  [0119]  [0121] 
US7445912B   [0117] 
EP14799913   [0229] 
US2014049509W   [0229] 
WO61861989A   [0229] 

New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids   [0094] 
Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies   [0106] 
Lyophilization of Biopharmaceuticals, editors Costantino & Pekal. Lyophilization of Biopharmaceuticals   [0106] 
Expression and characterization of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1   [0106] 
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein   [0106] 
Nature   [0117] 
Arch Oral Biol.   [0117] 
Amino Acids   [0117] 
Agric. Food Chem   [0117] 
Di-tyrosine as a product of oxidative stress and fluorescent probe   [0118] 
Determining protein-protein interactions by oxidative cross-linking of a glycine-glycine-histidine fusion protein   [0118] 
NMR Structure of a Monomeric Intermediate on the Evolutionarily Optimized Assembly Pathway of a Small Trimerization Domain   [0127] 
A conserved trimerization motif controls the topology of short coiled coils   [0127] 
An intracellular role for the C1q-globular domain   [0127] 
The reovirus σ-1 aspartic acid sandwich: A trimerization motif poised for conformational change   [0127] 
Soluble Mimetics of Human Immunodeficiency Virus Type 1 Viral Spikes Produced by Replacement of the Native Trimerization Domain with a Heterologous Trimerization Motif: Characterization and Ligand Binding Analysis   [0127] 
Very fast folding and association of a trimerization domain from bacteriophage T4 fibritin   [0127] 
Creation of hybrid nanorods from sequences of natural trimeric fibrous proteins using the fibritin trimerization motif   [0127] 
Anal. Biochem.   [0134] 
Biol. Chem.   [0134] 
Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity   [0143] 
A comparative immunogenicity study in rabbits of disulfide-stabilized proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and momomeric gp120   [0143] 
CRC Crit. Ref. Biomed. Eng.   [0155] 
Surgery   [0155] 
N. Engl. J. Med.   [0155] 
Medical Applications of Controlled Release   [0155] 
Drug Product Design and Performance   [0155] 
Macromol. Sci. Rev. Macromol. Chem.   [0155] 
Science   [0155] 
Ann. Neurol.   [0155] 
J. Neurosurg   [0155] 
Medical Applications of Controlled Release   [0155] 
Science   [0155] 
Influenza virus vaccine based on the conserved hemagglutinin stalk domain   [0186] 
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses   [0186] 
1976 and 2009 H1N1 Influenza Virus Vaccines Boost Anti-Hemagglutinin Stalk Antibodies in Humans   [0186] 
Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice   [0186] 
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination   [0186] 
The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region   [0186] 
Antibody recognition of a highly conserved influenza virus epitope   [0186] 
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes   [0186] 
Broadly neutralizing antibodies against influenza virus and prospects for universal therapies   [0186] 
A highly conserved neutralizing epitope on group 2 influenza A viruses   [0186] 
Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA   [0186] 
Highly conserved protective epitopes on influenza B viruses   [0186] 
A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins   [0186] 
Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine   [0186] 
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses   [0186] 
Flexibility involving the intermolecular dityrosyl cross-links of enzymatically polymerized calmodulin   [0186] 
Dityrosine: preparation, isolation, and analysis   [0186] 
Dityrosine formation in calmodulin: cross-linking and polymerization catalyzed by Arthromyces peroxidase   [0186] 
Formation of dityrosine cross-links during breadmaking   [0186] 
Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection   [0186] 
Synthesis and properties of crosslinked recombinant pro-resilin   [0186] 
Protein aggregation and its inhibition in biopharmaceutics   [0186] 
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target   [0186] 
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1   [0186] 
Broad neutralization coverage of HIV by multiple highly potent antibodies   [0186] 
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures   [0186] 
C. Conformational-Locking of Cleaved HIV-1 gp140 Trimers by Targeted Dityrosine Bonds   [0186] 
Influenza: old and new threats   [0186] 
Influenza as a bioterror threat: the need for global vaccination   [0186] 
Preparing for the next pandemic   [0186] 
Vaccine process technology   [0186] 
Personal Communication   [0186] 
Formation of dityrosine cross-links in proteins by oxidation of tyrosine residues   [0186] 
Recombinant protein vaccines produced in insect cells   [0186] 
FluBlok, a next generation influenza vaccine manufactured in insect cells   [0186] 
Budding capability of the influenza virus neuraminidase can be modulated by tetherin   [0186] 
Personal Communication   [0186] 
Palese P: The biology of influenza viruses   [0218] 
Influenza: options to improve pandemic preparation   [0218] 
Orthomyxoviridae: The Viruses and their Replication.   [0218] 
Molecular architecture ofnative HIV-1 gp120 trimers   [0218] 
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9   [0218] 
Resurrected pandemic influenza viruses   [0218] 
Animal models for evaluation of influenza vaccines   [0218] 
Healthcare epidemiology: the current status of planning for pandemic influenza and implications for health care planning in the United States   [0218] 
Seasonal influenza vaccines   [0218] 
Vaccine Process Technology   [0218] 
Response to a monovalent 2009 influenza A (H1N1) vaccine   [0218] 
Antibody recognition of a highly conserved influenza virus epitope   [0218] 
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes   [0218] 
Broadly neutralizing antibodies against influenza virus and prospects for universal therapies   [0218] 
A highly conserved neutralizing epitope on group 2 influenza A viruses   [0218] 
A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses   [0218] 
A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins   [0218] 
Palese P: Influenza virus vaccine based on the conserved hemagglutinin stalk domain   [0218] 
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses   [0218] 
Anderson SR: Dityrosine: preparation, isolation, and analysis   [0218] 
Dityrosine formation in calmodulin: cross-linking and polymerization catalyzed by Arthromyces peroxidase   [0218] 
Formation of dityrosine by human salivary lactoperoxidase in vitro   [0218] 
Peroxidase-catalysed formation of dityrosine, a protein crosslink, in human periodontal ligament collagen   [0218] 
Synthesis and properties of crosslinked recombinant pro-resilin   [0218] 
Tyrosine oxidation products: analysis and biological relevance   [0218] 
Tyrosine cross-links: molecular basis of gluten structure and function   [0218] 
The role of dityrosine formation in the crosslinking of CUT-2, the product of a second cuticlin gene of Caenorhabditis elegans   [0218] 
Chemiluminescence from bamboo shoot cut   [0218] 
Modification in amino acids of Dead Sea Scroll Parchments   [0218] 
N,N'-Bisformyl dityrosine is an in vivo precursor of the yeast ascospore wall   [0218] 
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target   [0218] 
HIV-1 and influenza antibodies: seeing antigens in new ways   [0218] 
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus   [0218] 
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1   [0218] 
Animal Models for Influenza Virus Pathogenesis and Transmission   [0218] 
FluBlok, a next generation influenza vaccine manufactured in insect cells   [0218] 
Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin   [0218] 
Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer   [0218] 
Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies   [0218] 
The Ferret Model for Influenza   [0218] 
Towards universal influenza vaccines?   [0218] 
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus   [0218] 
A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets   [0218] 
Egg allergy and influenza vaccination   [0218] 
Influenza vaccines: the good, the bad, and the eggs   [0218] 
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection   [0218] 
Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design   [0218] 
Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity   [0218] 
Seasonal influenza vaccines: evolutions and future trends   [0218] 
Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins   [0218] 
Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain   [0218] 
PNAS   [0224]